A High efficacy of Artemether–Lumefantrine and Artesunate-Amodiaquine for the treatment of uncomplicated falciparum malaria in Massokory, Mondo and Dourbali provinces (Chad).
DOI:
https://doi.org/10.14738/jbemi.92.12196Keywords:
Keywords: Plasmodium falciparum, High efficacy of Artemether–Lumefantrine and Artesunate-Amodiaquine, uncomplicated malaria, ChadAbstract
Artemether-Lumefantrine (AL) and Artesunate-Amodiaquine (ASAQ) are recommended for the treatment of uncomplicated malaria in Chad. The objective of this study was to evaluate the High efficacy of Artemether–Lumefantrine and Artesunate-Amodiaquine for the treatment of uncomplicated falciparum malaria in Massokory, Mondo and Dourbali provinces (Chad).The study was carried out in 2019, 1113 patients children aged from 6 to 60 months were randomly assigned treatment with Artemether-Lumefantrine and Artesunate-Amodiaquine and followed up for 28 days. Primary endpoint was the treatment efficacy over 28 days. The early treatment failure was (0.13%) in AL group and (0.17%) in ASAQ group. No early clinical failure was found. Adequate clinical and parasitological responses were significantly higher in Artesunate-Amodiaquine group (ASAQ) (99.82% versus (99.10%) in Artemether-Lumefantrine (AL) group, p = 0.0009). All treatments had a similar and good tolerability profile that confirm the high efficacy of the first- and the newly recommended alternative ACT for treatments for uncomplicated falciparum malaria in Chad. The high parasite density clearance suggests absence of suspected artemisinin resistance, defined as delayed parasite clearance
References
REFERENCES
. Wongsrichanalai C, Sibley CH. Fighting drug-resistant Plasmodium falciparum: the challenge of artemisinin resistance. Clin Microbiol Infect. 2013;19 (10):908–916.
. Taylor SM, Parobek CM, Deconti DK, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis. 2015; 211 (5):680–688.
. Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev. 2017; 41(1):34–48.
. World Health Organization. Methods for Surveillance of Antimalarial Drug Efficacy. Geneva: World Health Organization; 2009.
. Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014; 505(7481):50–55.
. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361(5):455–467.
. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379(9830):1960–1966.
. Kamau E, Campino S, Amenga-Etego L, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis. 2015;211(8):1352–1355.
. Ogouyemi-Hounto A, Damien G, Deme AB, et al. Lack of artemisinin resistance in Plasmodium falciparum in northwest Benin after 10 years of use of artemisinin-based combination therapy. Parasite. 2016; 23:28.
. World Health Organization, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. http://www.emro.who.int/rbm/ publications/protocolwho.pdf.
. Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, Niare-Doumbo S, Coulibaly D, Kone AK, CissokoY, Tekete M, Fofana B, Dicko A, Diallo DA, Wellems TE, Kwiatkowski D, Plowe CV, 2003. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 69: 558–563.
. Dorsey G, Kamya MR, Ndeezi G, Babirye JN, Phares CR, Olson JE, Katabira ET, Rosenthal PJ, 2000. Predictors of chloroquine treatment failure in children and adults with falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg 62: 686–692.
. Ittarat W, Pickard AL, Rattanasinganchan P, Wilairatana P, Looareesuwan S, Emery K, Low J, Udomsangpetch R, Meshnick SR, 2003. Recrudescence in artesunate-treated patients with falciparum malaria is dependent of parasite burden not on parasite factors. Am J Trop Med Hyg 68: 147–152.
. Talisuna AO, Bloland P, D’Alessandro U, 2004. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 17: 235–254.
. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P, 1995. Mechanisms underlying the monocyte-mediated antibodydependent killing of Plasmodium falciparum asexual bloodstages. J Exp Med 182: 409–418.
. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, Holder AA, Riley EM, 1996. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 173: 765–769.
. Ter Kuile FO, Luxemburger C, Nosten F, Thwai KL, Chongsuphajaisiddhi T, White NJ, 1995. Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 89: 660–664.
. Ehrhardt S, Mockenhaupt FP, Agana-Nsiire P, Mathieu A, Anemana SD, Stark K, Otchwemah RN, Bienzle U, 2002. Efficacy of chloroquine in the treatment of uncomplicated, Plasmodium falciparum malaria in northern Ghana. Ann Trop Med Parasitol 96: 239–247.
. Rogier C, Tall A, Diagne N, Fontenille D, Spiegel A, Trape JF, 1999. Plasmodium falciparum clinical malaria: lessons from longitudinal studies in Senegal. Parassitologia 41: 255–259.
. White NJ, 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41: 1413–1422.
. White N, 1999. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 354: 739.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Mahamat Alio Hamit
This work is licensed under a Creative Commons Attribution 4.0 International License.
